Shire Uses Foresight To Expand In Ophthalmology
Shire acquired Foresight Biotherapeutics for $300 million, gaining a late-stage drug for pink eye that will be a commercial complement to lifitegrast.
Shire acquired Foresight Biotherapeutics for $300 million, gaining a late-stage drug for pink eye that will be a commercial complement to lifitegrast.